Skip to content
Search

Latest Stories

Pharmacy technicians can supply medicines under PGDs from end of this month

Pharmacy technicians can supply medicines under PGDs from end of this month

There will be no immediate change in the provision of community pharmacy services

New amendments to the Human Medicines Regulations will soon allow registered pharmacy technicians to supply and administer medicines under Patient Group Directions (PGDs).

Laid before Parliament at the end of May, the legislative changes will come into effect from June 26, 2024, the Community Pharmacy England (CPE) announced today.


The introduction of this new legislation follows an announcement made by the Department of Health and Social Care (DHSC) earlier this year.

The regulatory adjustments provide the legal framework for pharmacy technicians to engage in the supply and administration of medicines under PGDs in the course of their professional practice. However, there will be no immediate change in the provision of community pharmacy services, the CPE noted

“Any updates to services first need to be considered in negotiations and, where agreed, the relevant service directions and specifications would then be amended,” it added.

Gordon Hockey, Community Pharmacy England's Director of Legal Affairs, commented, “As the clinical skills of community pharmacists are put to greater use through services such as Pharmacy First, it is important to ensure that pharmacies can make best use of skill mix across the whole team.”

The DHSC conducted a consultation on the use of PGDs by pharmacy technicians last year, which the Committee responded to positively.

CPE noted that this development, coupled with proposed legislative changes in the Supervision Consultation (the outcome of which is still pending), will enable pharmacy technicians to fully utilise their skills and knowledge.

Malcolm Harrison, CEO of the Company Chemists’ Association (CCA), highlighted that this move is significant in adapting the workforce to meet future needs.

“The CCA has long campaigned in favour of pharmacy technicians being allowed to supply and administer medicines using Patient Group Directions (PGDs).

“We are delighted this change has come through which will further harness the skills of registered pharmacy technicians, who already play an integral role in community pharmacy. This is an important step in changing the workforce to reflect the needs of the future and offers a route to increasing vital future clinical capacity.

Empowering the workforce to move into the future and meet patient needs is a great first step,” he said.

He further urged NHS England to commission services ambitiously, along with providing additional funding, so that the sector can benefit from this change.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less